A supervised, in-office treatment option for adults who have not found relief with traditional antidepressant treatment.
Carolina Psychological Health Services offers Spravato® treatment in a calm, supportive clinical setting. Our REMS‑certified team provides careful monitoring, clear patient education, and coordination with your existing care providers throughout the treatment process.
SPRAVATO® (esketamine) nasal spray is a prescription medication used in adults for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in certain treatment settings.
Spravato® contains esketamine and is administered as a nasal spray under the supervision of a provider.
Because of important safety requirements, Spravato treatment is provided only in certified healthcare settings where patients can be monitored after dosing.
Spravato® treatment is supported by clinical trial data and real-world studies involving adults with treatment-resistant depression.
In one reported study, 22.5% of patients receiving Spravato® achieved remission after four weeks of treatment.
In the same study, 7.6% of patients receiving placebo achieved remission at week four.
Clinical trials demonstrated improvement in depressive symptoms as early as 24 hours after the first dose compared with placebo.
Our team guides you through each step, from consultation and insurance review to treatment-day preparation, monitoring, and follow-up.
We review your history, current symptoms, prior treatments, and whether Spravato® may be appropriate.
Our team helps evaluate coverage requirements and prior authorization steps when applicable.
If approved, we schedule visits and explain how to prepare for your appointments.
You self-administer Spravato® nasal spray under supervision in our office.
Patients remain in the office for observation for at least two hours before discharge.
Each visit is designed to be structured, supportive, and carefully monitored so you know what to expect every step of the way.
Spravato® treatment is provided only in certified healthcare settings because patients must be monitored after each treatment session for safety.
Spravato® is self-administered under the supervision of a healthcare provider in a certified treatment setting.
Patients remain in the clinic for observation for at least two hours after dosing before being discharged.
Monitoring may include blood pressure checks, observation for sedation or dissociation, and confirmation that you are ready to leave safely.
Spravato® treatment often requires insurance verification and prior authorization before treatment can begin. Our team helps guide patients and referring providers through the process so expectations are clear at every step.
Coverage varies by plan, but we assist with benefit verification, coordination with insurance providers, and treatment scheduling once approvals are in place.
Whether you are exploring treatment for yourself, helping a loved one, or referring a patient, our team works to make the process organized, transparent, and supportive.
We review your benefits and help determine potential coverage and prior authorization requirements.
Schedule a consultation to discuss eligibility, treatment planning, and next steps.
Our team coordinates care and can provide referral guidance and communication with your practice.
We want patients and families to feel informed before getting started. Here are answers to some of the questions we hear most often.
Plan for approximately 2–3 hours, including treatment time and the required post-treatment monitoring period.
No. Patients should arrange transportation home after each treatment visit and should not drive until the next day after a restful sleep.
No. Spravato® is administered only in a certified healthcare setting under the supervision of a provider, followed by monitoring after treatment.
Spravato® contains esketamine and is administered only in certified healthcare settings under REMS requirements. Your provider can help explain whether it may be appropriate for your situation.
When appropriate, our team coordinates care with your referring psychiatrist, therapist, or other treating provider to support continuity of care.
The first step is to contact our team for a consultation. We can review eligibility, answer questions about treatment, and discuss insurance and referral steps.
Some patients report symptom relief within hours or days after dosing, though responses vary.
Yes — you must have a ride home. Driving same day is not permitted due to sedation risk.
No — it is only administered in certified in-office settings and requires monitoring.
Many plans provide coverage with prior authorization. Our team will assist.
Your clinician will guide medication adjustments based on your individualized plan.
SPRAVATO® (esketamine) nasal spray, in conjunction with an oral antidepressant, is indicated for the treatment of treatment-resistant depression (TRD) in adults. SPRAVATO®, in conjunction with an oral antidepressant, is also indicated for the treatment of depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.
SPRAVATO® can cause serious side effects including sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors.
Please see the full Prescribing Information and Medication Guide for additional information.
The TMS Advanced Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.
The TMS Advanced Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).
TMS Advanced Therapy is only available by prescription. A doctor can help decide if TMS Advanced Therapy is right for you. Patients’ results may vary.
The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of TMS therapy (<0.1% per patient).
Since 1988, Carolina Psychological Health Services located in Jacksonville, NC, has been providing a full range of psychological and specialty services to clients of all ages throughout North Carolina.
TRICARE is a registered trademark of the Department of Defense, Defense Health Agency. All Rights Reserved.